Lindsay Ackerman, MD, FAAD, is a board-certified dermatologist in Phoenix, Arizona, and founder of Medical Dermatology Specialists, now part of US Dermatology Partners. She created SkinTellAgent, a multimedia educational nonprofit network built to educate how the skin reveals deeper truths of human health, and co-hosts HCPLive’s ABCs in Dermatology podcast. She is clinical faculty at the University of Arizona College of Medicine – Phoenix and has been an AAD delegate to the AMA since 2005.
Panelists discuss how oral Janus kinase (JAK) inhibitors offer advantages over biologics in specific clinical scenarios including patients needing rapid onset of action, those with comorbid arthralgia, head and neck involvement, needle fatigue, and environmental trigger sensitivity due to their broad anti-inflammatory effects.
Panelists discuss how the AHEAD recommendations establish evidence-based treatment targets requiring simultaneous achievement of skin clearance (Eczema Area and Severity Index [EASI]-90) and itch relief (itch score 0-1) within 3 to 6 months, fundamentally changing the standard of care by incorporating patient-reported outcomes alongside physician assessments.
Panelists discuss how Janus kinase (JAK) inhibitors represent a revolutionary advancement in atopic dermatitis treatment by targeting multiple cytokine pathways simultaneously at the intracellular level, offering broader therapeutic coverage than biologics that target only 1 or 2 specific cytokines.
Latanya Benjamin, MD, and Lindsay Ackerman, MD, joins The Medical Sisterhood in a live recording at AAD 2025 to discuss advocacy, mentorship, and empowerment.
A group of 9 experts reflect on what they are looking forward to most in 2025 following the AAD annual meeting.
Looking to the future of atopic dermatitis treatment, the panel discusses ongoing research and promising emerging therapies.
Focusing on clinical scenarios, experts on atopic dermatitis discuss how their treatment approaches vary depending on patient-specific factors.
Dermatologists outline the role of targeted therapies and JAK inhibitors in the treatment of patients with atopic dermatitis.
Following a review of findings from the LEVEL UP study, an expert on atopic dermatitis shares what we’ve learned from long-term data on upadacitinib and JAKi.
Jonathan Silverberg, MD, PhD, MPH, reviews findings from the LEVEL UP study investigating upadacitinib in patients with moderate-to-severe atopic dermatitis.
Lindsay S. Ackerman, MD, FAAD, and Jonathan Silverberg, MD, PhD, MPH, provide clinical insights on best practices for monitoring patients with atopic dermatitis who are receiving JAK inhibitors.
Experts on atopic dermatitis compare the safety profile of JAK inhibitors with traditional and more advanced treatments currently available for patients.
A panel of dermatologists discuss the evolution of JAK inhibitors for atopic dermatitis and how they fit into current treatment paradigms.
Focusing on the complex pathophysiology of atopic dermatitis, Lindsay S. Ackerman, MD, FAAD, discusses the importance of looking beyond type 2 inflammation while treating patients.
Dermatologists outline unmet needs in the treatment landscape for atopic dermatitis and discuss how to potentially improve the standard of care for patients with atopic dermatitis.
The panel provides comprehensive insights on treating atopic dermatitis and how recent advances have elevated standard-of-care treatment practices in dermatology practices.
A panel of experts on atopic dermatitis discuss how patient preferences are taken into account when choosing between available treatments.
Jonathan Silverberg, MD, PhD, MPH, offers insights on the role of patient-reported outcomes in informing treatment decisions for patients with atopic dermatitis.
Lindsay S. Ackerman, MD, FAAD, provides clinical insights on best practices for evaluating treatment response in patients with atopic dermatitis.
Lindsay S. Ackerman, MD, FAAD, and Jonathan Silverberg, MD, PhD, MPH, discuss how patient goals inform treatment decisions for patients with atopic dermatitis.
Experts on atopic dermatitis describe the burden of the disease and provide clinical insights on counseling patients who are experiencing sleep disturbances.
A panel of dermatologists discuss the heterogeneity of clinical presentations of atopic dermatitis and offer ways to reduce misdiagnosis.
